NASDAQ:SPRO - Spero Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$13.11 -0.14 (-1.06 %)
(As of 03/20/2019 04:00 PM ET)
Previous Close$13.25
Today's Range$13.10 - $13.49
52-Week Range$5.52 - $19.00
Volume71,170 shs
Average Volume89,975 shs
Market Capitalization$225.75 million
P/E Ratio-5.04
Dividend YieldN/A
Beta2.96
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; and SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting. The company also develops SPR206, an agent that is in preclinical development stage to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic, which is in preclinical development stage for the treatment of pulmonary non-tuberculous mycobacterial infections. Spero Therapeutics, Inc. has collaboration with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries, as well as has option to rights to SPR741 in the territory. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Receive SPRO News and Ratings via Email

Sign-up to receive the latest news and ratings for SPRO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SPRO
CUSIPN/A
Phone857-242-1600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.97 million
Book Value$6.73 per share

Profitability

Net Income$-41,660,000.00
Net Margins-1,050.48%

Miscellaneous

EmployeesN/A
Market Cap$225.75 million
Next Earnings Date5/9/2019 (Estimated)
OptionableOptionable

Spero Therapeutics (NASDAQ:SPRO) Frequently Asked Questions

What is Spero Therapeutics' stock symbol?

Spero Therapeutics trades on the NASDAQ under the ticker symbol "SPRO."

How were Spero Therapeutics' earnings last quarter?

Spero Therapeutics Inc (NASDAQ:SPRO) announced its quarterly earnings results on Thursday, March, 14th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.15. The company had revenue of $1.69 million for the quarter, compared to analysts' expectations of $0.84 million. Spero Therapeutics had a negative net margin of 1,050.48% and a negative return on equity of 43.63%. View Spero Therapeutics' Earnings History.

When is Spero Therapeutics' next earnings date?

Spero Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, May 9th 2019. View Earnings Estimates for Spero Therapeutics.

What price target have analysts set for SPRO?

4 analysts have issued twelve-month target prices for Spero Therapeutics' shares. Their predictions range from $9.00 to $30.00. On average, they anticipate Spero Therapeutics' stock price to reach $23.50 in the next year. This suggests a possible upside of 79.3% from the stock's current price. View Analyst Price Targets for Spero Therapeutics.

What is the consensus analysts' recommendation for Spero Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spero Therapeutics in the last year. There are currently 1 sell rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Spero Therapeutics.

What are Wall Street analysts saying about Spero Therapeutics stock?

Here are some recent quotes from research analysts about Spero Therapeutics stock:
  • 1. According to Zacks Investment Research, "Spero Therapeutics Inc. is a multi-asset, clinical-stage biopharmaceutical company. It focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections. Spero Therapeutics Inc. is based in CAMBRIDGE, United States. " (3/20/2019)
  • 2. Cantor Fitzgerald analysts commented, "We rate SPRO Overweight. As the company advances its pipeline toward commercialization, we expect upward earnings revisions and multiple expansion to levels not reflected in FactSet consensus expectations to drive SPRO’s stock higher. Valuation Summary We use a blend of EV/EBITDA and DCF analysis to arrive at our $27 12-month price target. The Disclosure Section may be found on pages 3 – 4.Valuation We use a blend of EV/EBITDA and DCF analysis to arrive at our $27 12-month price target." (2/26/2019)

Has Spero Therapeutics been receiving favorable news coverage?

Media stories about SPRO stock have trended somewhat positive recently, according to InfoTrie Sentiment. The research firm scores the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Spero Therapeutics earned a news impact score of 1.3 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the company's share price in the next few days.

Who are some of Spero Therapeutics' key competitors?

What other stocks do shareholders of Spero Therapeutics own?

Who are Spero Therapeutics' key executives?

Spero Therapeutics' management team includes the folowing people:
  • Mr. Ankit Mahadevia M.D., MBA, Co-Founder, CEO, Pres & Director (Age 38)
  • Mr. Joel D. Sendek, CFO & Treasurer (Age 52)
  • Ms. Cristina Larkin, Chief Operating Officer (Age 49)
  • Dr. Thomas R. Parr Jr., Chief Scientific Officer (Age 65)
  • Ms. Sharon Klahre, Director of Investor Relations

When did Spero Therapeutics IPO?

(SPRO) raised $75 million in an initial public offering (IPO) on Thursday, November 2nd 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel served as the underwriters for the IPO and Oppenheimer & Co. was co-manager.

Who are Spero Therapeutics' major shareholders?

Spero Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (2.84%), BlackRock Inc. (2.29%), UBS Oconnor LLC (0.98%), UBS Oconnor LLC (0.98%), Fosun International Ltd (0.94%) and Northern Trust Corp (0.56%). Company insiders that own Spero Therapeutics stock include Ankit Mahadevia, Casper Breum, Cristina Larkin, Joel Sendek and Plc Glaxosmithkline. View Institutional Ownership Trends for Spero Therapeutics.

Which institutional investors are selling Spero Therapeutics stock?

SPRO stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, UBS Oconnor LLC and UBS Oconnor LLC. Company insiders that have sold Spero Therapeutics company stock in the last year include Ankit Mahadevia, Cristina Larkin and Joel Sendek. View Insider Buying and Selling for Spero Therapeutics.

Which institutional investors are buying Spero Therapeutics stock?

SPRO stock was purchased by a variety of institutional investors in the last quarter, including Fosun International Ltd, Bank of America Corp DE, Two Sigma Investments LP, BlackRock Inc., IHT Wealth Management LLC, Rhumbline Advisers, Bank of New York Mellon Corp and PNC Financial Services Group Inc.. Company insiders that have bought Spero Therapeutics stock in the last two years include Casper Breum, Cristina Larkin, Joel Sendek and Plc Glaxosmithkline. View Insider Buying and Selling for Spero Therapeutics.

How do I buy shares of Spero Therapeutics?

Shares of SPRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Spero Therapeutics' stock price today?

One share of SPRO stock can currently be purchased for approximately $13.11.

How big of a company is Spero Therapeutics?

Spero Therapeutics has a market capitalization of $225.75 million and generates $3.97 million in revenue each year. The company earns $-41,660,000.00 in net income (profit) each year or ($2.60) on an earnings per share basis.

What is Spero Therapeutics' official website?

The official website for Spero Therapeutics is http://www.sperotherapeutics.com.

How can I contact Spero Therapeutics?

Spero Therapeutics' mailing address is 675 Massachusetts Avenue 14th Floor, Cambridge MA, 02139. The company can be reached via phone at 857-242-1600 or via email at [email protected]


MarketBeat Community Rating for Spero Therapeutics (NASDAQ SPRO)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  121 (Vote Outperform)
Underperform Votes:  107 (Vote Underperform)
Total Votes:  228
MarketBeat's community ratings are surveys of what our community members think about Spero Therapeutics and other stocks. Vote "Outperform" if you believe SPRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPRO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel